Respiratory chain (RC) complex defects are hallmarks of mitochondrial disease that often provide the first diagnostic evidence for a mitochondrial disorder and guide subsequent DNA analysis of the mitochondrial DNA (mtDNA) and nuclear genes encoding mitochondrial proteins.^[@R1]^ In a substantial proportion of cases, it is not possible to reach a molecular diagnosis, and it is assumed that most of these patients carry undetected mutations in genes coding for mitochondrial proteins. This report presents 5 patients with heterogeneous phenotypes and biochemical features of RC deficiency; however, the molecular diagnosis is not mitochondrial disease.

METHODS {#s1}
=======

Patients with biochemical evidence of RC deficiencies measured by standard methods in accredited laboratories in whom mtDNA mutations had been excluded were selected from a cohort of 60 patients for whole-exome sequencing.^[@R1]^ The diagnosis of a mitochondrial RC deficiency was based on the recently published consensus paper by the Mitochondrial Medicine Society (USA).^[@R2]^ Coverage and depth statistics of exome sequencing for each patient and the bioinformatic prediction for each mutation are listed in tables e-1 and e-2 at [Neurology.org/ng](10.1212/NXG.0000000000000006).

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

Informed consent was obtained from all participants in accordance with protocols approved by local institutions and research ethics committees.

RESULTS {#s2}
=======

Patient 1 presented with generalized muscular hypotonia, failure to thrive, liver dysfunction, atrial septal defect, and severe immunodeficiency. Based on the biochemical defect of complex I (50%) and IV (80% rest-activity) in skeletal muscle, mitochondrial disease was suggested. Exome sequencing identified a homozygous mutation c.587T\>C, p.Leu196Pro in the *ORAI1* gene, which is predicted to be deleterious with 6 different prediction programs (table e-2) and is located next to a pathogenic mutation (p.Leu194Pro).^[@R3]^ *ORAI1* encodes a calcium release-activated calcium channel protein that allows cellular calcium influx^[@R3]^ and may alter mitochondrial calcium metabolism, leading to RC deficiency. Autosomal recessive mutations in *ORAI1* have previously been described in association with severe combined immunodeficiency and congenital myopathy and in dominantly inherited tubular aggregate myopathy with hypocalcemia.^[@R3]^

Patient 2 presented with a juvenile-onset slowly progressive myopathy and limb-girdle muscle weakness. The clinical diagnosis of a mitochondrial myopathy was based on the detection of cytochrome *c* oxidase--negative fibers and decreased complex IV activity in muscle (80% rest-activity). A known pathogenic homozygous c.1715G\>A, p.Arg572Gln mutation was detected in *CAPN3* encoding a skeletal muscle-specific intracellular calcium-activated neutral protease, and its deficiency leads to oxidative stress and potentially a secondary RC deficiency.^[@R4]^ This is a previously published pathogenic mutation and the only variant that segregated with the disease in the family. *CAPN3* mutations are common causes of limb-girdle muscular dystrophy type 2A (LGMD2A).^[@R4]^ Muscle biopsy shows a dystrophic pattern; however, disorganized mitochondria and reduced complex V levels were occasionally reported in a few patients with LGMD2A.^[@R4]^

Patient 3 presented with axial muscle weakness, ptosis, respiratory failure requiring ventilation, and reduced IV (80% rest-activity) and borderline complex I activities. We detected a homozygous frameshift mutation c.636delA, p.Lys212fs in the *COLQ* gene. Mutations of the acetylcholinesterase collagen-like tail subunit gene (*COLQ*) cause congenital myasthenic syndromes due to the deficiency of acetylcholine esterase at the synaptic endplate.^[@R5]^ The clinical phenotype includes hypotonia, muscle weakness, delayed motor development, ophthalmoparesis, and respiratory failure. No involvement of mitochondria has been suggested in previous patients to date.^[@R5]^

Patient 4 belonged to a large Hungarian Roma pedigree presenting with hypomyelination, hypoplasia of the cerebellum and corpus callosum, and spinal muscular atrophy. Muscle biopsy revealed reduced complex I (60% rest-activity) and IV (80% rest-activity). We identified a homozygous c.815G\>C, p.Ser272Thr mutation in a novel disease gene *EXOSC8* encoding an exosome subunit involved in AU-rich element (ARE)-containing messenger RNA (mRNA) degradation, and the altered myelination was due to abnormal degradation of ARE myelin proteins.^[@R6]^ The pathogenicity of the mutation was supported by the absence of EXOSC8 protein in myoblasts of the patient and by segregation with the disease in the large pedigree.^[@R6]^ A secondary RC defect in these patients may be related to abnormal degradation of ARE mRNAs of mitochondrial disease genes.

Patient 5 presented in childhood with epilepsy and learning difficulties and developed cerebellar ataxia, brisk reflexes, and nystagmus from age 45 years. Complex III defect (60% rest-activity) and low coenzyme Q~10~ (CoQ~10~) (60% of low normal) were detected in her muscle. We identified compound heterozygous pathogenic mutations in *ANO10* (c.132_133insT, p.Asp45Arg fs\*53 and c.1843G\>A, p.Asp615Asn).^[@R7]^ The pathogenicity of the missense variant c.1843G\>A, p.Asp615Asn has been confirmed by its detection in additional patients.^[@R8]^ CoQ~10~ supplementation resulted in clinical improvement, emphasizing the importance of low CoQ~10~ in the pathomechanism.^[@R7]^ *ANO10* encodes an anoctamin protein forming calcium-activated chloride channels, implying that an abnormal calcium metabolism may cause mitochondrial dysfunction in ANO10 deficiency.^[@R7]^

DISCUSSION {#s3}
==========

Typically, RC defects are associated with mutations in the mtDNA or in nuclear genes affecting mitochondrial proteins. The patients we present here had disease-causing (previously reported or nonsense) variants in nonmitochondrial disease genes, which would have been missed on targeted next-generation panels or on MitoExome analysis.^[@R9]^ Our data demonstrate that RC abnormalities may be secondary to various cellular processes, including calcium metabolism, neuromuscular transmission, and abnormal mRNA degradation; however, the role of mitochondria in these diseases needs further investigation ([figure](#F1){ref-type="fig"}). Secondary RC defects in patients with neurogenetic disease have previously been reported. For example, Alexander disease is caused by nuclear mutations encoding non-RC chain proteins, but patients exhibit biochemical and MRI findings typically found with RC abnormalities.^[@R10]^

![Detailed clinical and molecular genetic characteristics of patients in this study and localization of nuclear mutant proteins resulting in respiratory chain deficiencies\
(A) Table of clinical and molecular genetic characteristics of 5 patients with heterogeneous phenotypes and biochemical features of respiratory chain deficiency. (B) Crystal structure of the human exosome complex involved in RNA metabolism. EXOSC8 highlighted in pink. ORAI1, calcium channel located on the cell membrane. ANO10, calcium-activated chloride channel located on the cell membrane. CAPN3, an intracellular calcium-activated neutral protease isoform located within the sarcomere. COLQ protein, a collagen-like subunit associated with acetylcholinesterase in skeletal muscle. CoQ~10~ = coenzyme Q~10~.](NNG-D-15-00006FF1){#F1}

Faced with increasing numbers of published disease-causing variants, improved and more accessible sequencing techniques, and more comprehensive phenotype characterization, the clinician should keep an open mind when approaching genetic testing and not limit testing to predicted disease-causing variants in suspicion of mitochondrial disease.
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